Comparative Pharmacology
Head-to-head clinical analysis: TRIKAFTA COPACKAGED versus ZOKINVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIKAFTA COPACKAGED versus ZOKINVY.
TRIKAFTA (COPACKAGED) vs ZOKINVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trikafta is a combination of three drugs (elexacaftor, tezacaftor, ivacaftor) that target the defective CFTR protein. Elexacaftor and tezacaftor are CFTR correctors that facilitate the processing and trafficking of the F508del-CFTR protein, increasing its quantity at the cell surface. Ivacaftor is a CFTR potentiator that increases the channel open probability of CFTR at the cell surface, enhancing chloride transport.
ZOKINVY (lonafarnib) is a farnesyltransferase inhibitor (FTI) that inhibits the post-translational farnesylation of proteins, including lamin A and progerin, thereby preventing their abnormal accumulation in the nuclear envelope.
Two tablets (each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) orally once daily in the morning, plus one ivacaftor 150 mg tablet orally once daily in the evening, approximately 12 hours apart.
Adults: 100 mg orally twice daily (every 12 hours) with or without food.
None Documented
None Documented
Elexacaftor: ~24 hours; Tezacaftor: ~13.1 hours; Ivacaftor: ~12.5 hours. Steady state achieved within 7 days; allows once-daily dosing for elexacaftor/tezacaftor and every-12-hour dosing for ivacaftor.
Terminal elimination half-life 39 hours (range 28-51 h) after multiple dosing, supporting once-daily dosing.
Primarily hepatic metabolism; unchanged drug excreted renally <1% for elexacaftor, tezacaftor, and ivacaftor. Fecal excretion accounts for approximately 87.8% of total dose (elezacaftor), 72.2% (tezacaftor), and 87.8% (ivacaftor). Renal excretion is negligible.
Renal (47% as unchanged drug, 22% as metabolites) and biliary/fecal (31% as metabolites and unchanged drug).
Category C
Category C
CFTR Modulator
CFTR Modulator